agilon health inc (AGL)

Agilon Health's stock price has significantly declined, falling approximately 74.98% in the past six months and 64.99% over the past year. Key events include a second-quarter 2025 earnings miss, leading to the suspension of its 2025 financial guidance. The departure of CEO Steven Sell in August 2025, an $85 million write-down related to overstatements of risk-adjustment revenue, and a net loss of $104 million in Q2 2025 also impacted the stock. These financial missteps and leadership changes have led to legal investigations into potential securities law violations.

Agilon Health's revenue primarily comes from risk-based contracts with payers, particularly Medicare Advantage plans, receiving a fixed per-member-per-month fee. This model provides a stable revenue stream due to the consistent healthcare needs of seniors, the primary demographic served. While membership growth and changes in Medicare Advantage rates can introduce variability, the demand for the company's value-based care services is not inherently seasonal.

Agilon Health, Inc. is a healthcare company focused on transforming primary care for seniors by enabling community-based physicians to shift to a value-based care model. The company operates in the Health Services sector, offering a partnership model with data analytics, care coordination, and patient engagement tools. Agilon Health assumes financial risk for patient outcomes through risk-sharing agreements, allowing physicians to focus on quality care, primarily serving Medicare Advantage patients with services like chronic disease management and preventive care. The business model relies on fixed per-member-per-month payments to manage patient healthcare needs and costs.

Agilon Health operates across the United States, partnering with physician groups in multiple states. The company has expanded its presence to six U.S. markets, including Austin, Texas, Akron, Ohio, and Columbus, Ohio.

Agilon Health's brand reputation has been negatively impacted due to leadership instability, financial missteps, and legal scrutiny. The resignation of its CEO, suspension of financial guidance, and a stock plunge have raised questions about its operational integrity. Investigations into potential securities law violations, including alleged investor misstatements, insider trading, and delayed disclosure of material financial risks, have eroded investor trust.

Agilon Health's ownership includes institutional, retail, and individual investors. Major institutional owners include Clayton, Dubilier & Rice, LLC, Morgan Stanley, Capital World Investors, Fmr Llc, Vanguard Group Inc, ANCFX - AMERICAN FUNDS FUNDAMENTAL INVESTORS Class A, BlackRock, Inc., SMCWX - SMALLCAP WORLD FUND INC Class A, Capital International Investors, and VTSMX - Vanguard Total Stock Market Index Fund Investor Shares. Institutional investors hold a substantial portion of the company's stock, with figures ranging from approximately 34.36% to 96.36% across different reports. Insiders hold around 2.28% to 26.63% of the stock, while public and individual investors hold between 0% and 51.88%. Clayton, Dubilier & Rice, LLC, a private equity firm, was instrumental in the company's formation and remains a significant shareholder.